Back to discover
Disease

Malaria, Falciparum

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHMalaria, Falciparum
3
Publications
16
Clinical trials
1
Related proteins
2020
Latest publication
Current focus
Protozoan biologyTherapeutic developmentGenetics & risk factorsInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones3View
Results expected 2
Recently completed 1
Activity timeline3

Clinical trials

13 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
16
All trials
3
Active
9
Late-stage
6
Completed
Late-stage studies

A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and Vietnam

Phase 3 · Completed · University of Oxford

The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians

Phase 4 · Completed · Malaria Consortium

Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon

Phase 4 · Completed · Instituto Nacional de Salud. Peru

Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes

Phase 4 · Completed · London School of Hygiene and Tropical Medicine

In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014

Phase 4 · Completed · Centers for Disease Control and Prevention

Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania

Phase 4 · Completed · University of Copenhagen
Recently completed

A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and Vietnam

Phase 3 · Completed · University of Oxford

The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians

Phase 4 · Completed · Malaria Consortium

Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon

Phase 4 · Completed · Instituto Nacional de Salud. Peru

Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes

Phase 4 · Completed · London School of Hygiene and Tropical Medicine

In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014

Phase 4 · Completed · Centers for Disease Control and Prevention

Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania

Phase 4 · Completed · University of Copenhagen

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20032020
Major themes4
  • Genetic Predisposition to Disease1
  • Genome-Wide Association Study1
  • Immunization, Secondary1
  • Mutation, Missense1
Leading journals2
  • Nature medicine2
  • Nature communications1
Leading researchers8
  • Ariey F1
  • Arulanantham N1
  • Blanchard TJ1
  • Brown K1
  • Butcher G1
  • Campagne P1
  • Criscuolo A1
  • Cummings J1
Affiliations (unnormalised)6
  • Columbia University Irving Medical Center1
  • Institut Cochin1
  • Malaria Genetics and Resistance Unit-Institut Pasteur1
  • National Reference Laboratory (NRL)1
  • Rwanda Biomedical Centre (RBC)1
  • University of Gothenburg1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Protozoan Proteins2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.

Identifiers
MeSHMalaria, Falciparum
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.